Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza ) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting Nasdaq:ONTX

Press/Media

Period3 Dec 2018

Media coverage

1

Media coverage

  • TitleOnconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza ) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting Nasdaq:ONTX
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date3/12/18
    PersonsShyamala Navada, Lewis Silverman